These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 16279567

  • 1. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy.
    Berger W, Abelson MB, Gomes PJ, Beck M, Kimura S, Westbrook T, Storms W, Galant S.
    Ann Allergy Asthma Immunol; 2005 Oct; 95(4):361-71. PubMed ID: 16279567
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
    Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, Finn AF, Marple BF, Roland PS, Wall GM, Brubaker MJ, Dimas C, Potts SL, Silver LH, Barnes JR.
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
    [Abstract] [Full Text] [Related]

  • 3. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF.
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [Abstract] [Full Text] [Related]

  • 4. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
    Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G.
    Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar.
    Ratner PH, Hampel FC, Amar NJ, van Bavel JH, Mohar D, Marple BF, Roland PS, Wall GM, Brubaker MJ, Drake M, Turner D, Silver LH.
    Ann Allergy Asthma Immunol; 2005 Nov; 95(5):474-9. PubMed ID: 16312171
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL, Abelson MB, Ober A, Gotnes PJ.
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB, Turner D.
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 10. Olopatadine hydrochloride in children: efficacy and safety for perennial allergic rhinitis.
    Okubo K, Okuda M, Magara H, Kaneko K.
    Curr Med Res Opin; 2010 Jul; 26(7):1657-65. PubMed ID: 20443650
    [Abstract] [Full Text] [Related]

  • 11. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM.
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM, Tekelioglu Y, Turk A, Akyol N.
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [Abstract] [Full Text] [Related]

  • 13. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life.
    Condemi J, Schulz R, Lim J.
    Ann Allergy Asthma Immunol; 2000 May; 84(5):533-8. PubMed ID: 10831008
    [Abstract] [Full Text] [Related]

  • 14. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo.
    Hampel FC, Ratner PH, Amar NJ, van Bavel JH, Mohar D, Fairchild CJ, Wall GM, Brubaker MJ, Drake M, Crenshaw KM.
    Allergy Asthma Proc; 2006 May; 27(3):202-7. PubMed ID: 16913262
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge.
    Lanier BQ, Abelson MB, Berger WE, Granet DB, D'Arienzo PA, Spangler DL, Kägi MK.
    Clin Ther; 2002 Jul; 24(7):1161-74. PubMed ID: 12182260
    [Abstract] [Full Text] [Related]

  • 16. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.
    Meltzer EO, Casale TB, Nathan RA, Thompson AK.
    Ann Allergy Asthma Immunol; 1999 Oct; 83(4):311-7. PubMed ID: 10541423
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis.
    Moinuddin R, deTineo M, Maleckar B, Naclerio RM, Baroody FM.
    Ann Allergy Asthma Immunol; 2004 Jan; 92(1):73-9. PubMed ID: 14756468
    [Abstract] [Full Text] [Related]

  • 18. Impact on quality of life during an allergen challenge research trial.
    Ellis AK, Day JH, Lundie MJ.
    Ann Allergy Asthma Immunol; 1999 Jul; 83(1):33-9. PubMed ID: 10437814
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis.
    Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM.
    Allergy Asthma Proc; 2007 Jul; 28(6):716-23. PubMed ID: 18201438
    [Abstract] [Full Text] [Related]

  • 20. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
    Pipkorn P, Costantini C, Reynolds C, Wall M, Drake M, Sanico A, Proud D, Togias A.
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.